Industry
Real Estate - Services
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Loading...
Open
1.80
Mkt cap
45M
Volume
16K
High
1.91
P/E Ratio
-1.30
52-wk high
2.50
Low
1.80
Div yield
N/A
52-wk low
1.29
Portfolio Pulse from
November 08, 2024 | 12:00 am
Portfolio Pulse from
November 07, 2024 | 12:30 am
Portfolio Pulse from
November 06, 2024 | 10:00 pm
Portfolio Pulse from
November 06, 2024 | 3:15 am
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 8:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.